Ekaterina Kotelnikova
Associate Director for Discovery and Translational Science Consulting
Ekaterina is a highly experienced professional in bioinformatics consulting, with over 20 years of expertise in bioinformatics and systems biology. She holds a Ph.D. in molecular evolution and has a background in biophysics. Throughout her career, Ekaterina has led teams in both academic and commercial settings, specializing in drug discovery, patient subpopulation selection, and precision medicine applications using multi-omics approaches, network, and pathway analysis. She has been actively involved in establishing partnerships with interdisciplinary teams and has made significant contributions to grant applications and deliveries.
Driven by her passion for translational medicine, Ekaterina co-founded a company dedicated to NGS-based cancer treatment predictions. Working closely with molecular oncologists, bioinformaticians, and systems biologists, the company focused on the application of systems biology to precision medicine, benefiting from seed investments and grants.
Ekaterina plays a crucial role in client-facing activities and business development, conducting client needs assessments, exploring market opportunities, proposing innovative solutions, and successfully overseeing project management across various therapy areas, including oncology, neuromuscular, skin, rare, and autoimmune diseases.
Latest news
Clarivate Launches Derwent Patent Monitor to Enable Fast and Accurate Decision-making with AI
New enterprise solution streamlines IP and R&D patent reviews and accelerates freedom to operate, patentability, and infringement related decisions London, U.K. November 24, 2025. Clarivate Plc (NYSE:CLVT), a leading global provider…
Clarivate RiskMark Wins 2025 LegalTech Breakthrough Award For “LegalTech Predictive AI Solution of the Year”
Annual awards program recognizes companies and products driving innovation in the global legal technology industry AI-powered RiskMark delivers near-instant, data-backed insights London, U.K. November 13, 2025. Clarivate Plc (NYSE:CLVT), a…